NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

Tags: lung cancer


Immunotherapy prolongs survival, but at what cost? Washington Post needed more on treatment downsides


Without any independent sources providing insight, readers of TIME’s coverage on lung cancer immunotherapy mostly left in the dark


Reuters lets Roche make data-free claims about drug’s impact on lung cancer survival


NPR story says older patients ‘can benefit’ from lung cancer surgery, but study didn’t show that

2 5/21/2015

Post coverage of new lung cancer test misses on caveats, costs, and harms

3 5/13/2015

The Times offers informative breakdown on the value of lung cancer screening


New drug Opdivo successfully ends lung cancer trial

1 4/15/2013

Freezing Treatment May Help Destroy Lung Tumors: Study


Women who ate more soy survive lung cancer better, study finds


Dogs Sniff Out Lung Cancer in Humans